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Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor
responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional
programs that regulate the fate of CAR-T cells after infusion remain poorly understood. Here
we perform TCRB sequencing, integration site analysis, and single-cell RNA sequencing
(scRNA-seq) to profile CD8+ CAR-T cells from infusion products (IPs) and blood of patients
undergoing CD19 CAR-T immunotherapy. TCRB sequencing shows that clonal diversity of
CAR-T cells is highest in the IPs and declines following infusion. We observe clones that
display distinct patterns of clonal kinetics, making variable contributions to the CAR-T cell
pool after infusion. Although integration site does not appear to be a key driver of clonal
kinetics, scRNA-seq demonstrates that clones that expand after infusion mainly originate
from infused clusters with higher expression of cytotoxicity and proliferation genes. Thus, we
uncover transcriptional programs associated with CAR-T cell behavior after infusion.
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Lymphodepletion chemotherapy followed by infusion ofCD19-specific chimeric antigen receptor modified-T (CAR-T) cells has produced durable responses in a subset of
patients with relapsed and refractory B-cell malignancies1–8. In
vivo CAR-T cell proliferation after infusion is important for anti-
tumor efficacy and may depend on several factors including the
design of the CAR construct, the quality of T cells for CAR T
manufacturing, the manufacturing process, the lymphodepletion
regimen, infused cell phenotype, and the tumor burden and
tumor microenvironment3,4,9–18. Despite the importance of
in vivo CAR-T cell expansion to clinical response and toxicities of
CAR-T cell therapy, little is known about the clonal composition
of CAR-T cells in the infusion product (IP), how clonal com-
position of CAR-T cells changes in the recipient after adoptive
transfer, and how distinct transcriptional signatures in the CAR-T
IP might affect cell fate in vivo.
We previously reported in a small subset of patients with acute
lymphoblastic leukemia (ALL) that CAR-T cells were polyclonal,
both in the IP and at the peak of expansion in the recipient4.
Another group reported one patient in whom a single CD8+
CAR-T cell clone, in which the transgene had integrated into the
TET2 locus, dominated at the peak of in vivo expansion19. These
highly disparate patterns suggest variability in the clonal com-
position of infused CAR-T cells and potential differences in the
ability of individual CAR-T cell clones to expand after adoptive
transfer. Thus, we examine the T cell receptor beta (TCRB)
repertoire and lentiviral integration sites of CD8+ CAR-T cells
isolated from the IP and from blood of patients treated with
CD19-targeted CAR-T cell immunotherapy. We find distinct
patterns of clonal behavior that contribute to the CAR-T cell
population in the recipient after infusion. Using single-cell RNA
sequencing (scRNA-seq), we identify transcriptionally distinct
clusters of infused CD8+ CAR-T cells that differ in their con-
tribution to the CAR-T cell repertoire in blood after infusion.
Results
Clonal diversity of CAR-T cells decreases after infusion. To
better understand changes in the composition of CAR-T cells
after infusion, we studied a cohort of patients (n= 10) who
received CD19-specific CAR-T cells manufactured from bulk
CD4+ T cells and CD8+ central memory-enriched (TCM) cells,
which were infused in a 1:1 ratio of CD4+:CD8+ CAR-T cells.
These patients were representative of the study population in
terms of age, sex, lymphodepletion therapy, cell dose, adverse
events, and clinical outcome (Supplementary Table 1). Analysis of
CAR-T cell expansion following infusion showed that CD8+
CAR-T cells reached peak counts between 1 and 2 weeks post
infusion and declined thereafter (Fig. 1a). To study how the CD8+
CAR-T cell repertoire changes during in vivo expansion and
contraction, we performed high-throughput sequencing of the
TCRB CDR3 region in CD8+ CAR-T cells isolated from the IPs,
from blood early after infusion (day 7–14, early), and from blood
after the peak of CAR-T cell expansion (day 26–30, late)20. We
found that multiple TCRB gene families were represented in
CD8+ CAR-T cells isolated from the IP and from blood after
infusion (Supplementary Fig. 1). Examination of the unique
TCRB sequences confirmed that CD8+ CAR-T cells were highly
polyclonal in the IP and after adoptive transfer (Supplementary
Table 2).
We evaluated the similarity of the TCRB repertoire between
CD8+ CAR-T cells in the IP and in the blood at early and late
time points using the Morisita index21. A Morisita index of 0
indicates no TCRB sequences are shared between two samples.
An index of 1 indicates that the repertoires are identical,
comprising the same clonotypes in the same proportions in each
sample. In all patients, we observed sharing of CAR-T cell
clonotypes between the IP and after adoptive transfer (Fig. 1b).
TCRB repertoire similarity was greater between CD8+ CAR-T
cells in the IP and those isolated early after infusion compared
with those isolated at the later time point (Fig. 1b), consistent
with increasing differences in the CD8+ CAR-T cell repertoire
over time after adoptive transfer.
Next, we analyzed changes in the clonal diversity of CD8+
CAR-T cells after adoptive transfer by calculating the Shannon
entropy index after adjusting for differences in sampling depth22.
Clonal diversity of CD8+ CAR-T cells was highest in the IP and
progressively declined over time in the blood (Fig. 1c). In
contrast, clonal diversity remained stable over time in EGFRt−
endogenous CD8+ T cells. As time after infusion increased, the
ten most prevalent clonotypes comprised an increasing propor-
tion of the CD8+ CAR-T cell repertoire (Fig. 1d), demonstrating
that decreased clonal diversity after infusion is partly due to
expansion of oligoclonal CAR-T cell populations.
CAR-T cells display different clonal kinetics after infusion. To
obtain insight into the contribution of individual CAR-T cell
clones in the IP to the in vivo CAR-T cell pool, we first deter-
mined whether the ten most prevalent clonotypes in the IP
remained dominant after infusion. We tracked the rank and
relative frequency of these clonotypes within the CD8+ CAR-T
cell repertoire over time (Fig. 2a, b). In several patients, such as
ALL-2 and ALL-3, a majority of the top ten clonotypes in the IP
remained among the top ten clonotypes after infusion, main-
taining a high relative frequency over time. In other patients, both
the rank and relative frequency of many of the top ten clonotypes
decreased considerably after infusion, suggesting that not all
prevalent clonotypes in the IP will contribute to the CAR-T cell
pool after infusion.
Next, we traced the origin of the ten most prevalent clonotypes
from the early and late time points (Fig. 3a, b). Several of the top
ten clonotypes from the early and late time points originated from
low-ranking clonotypes in the IPs whose relative frequency greatly
increased after infusion. Interestingly, the top ten clonotypes from
the early time point generally remained among the top ten
clonotypes at the late time point in most patients, except in NHL-1,
NHL-3, and NHL-5. In these patients, several of the top ten
clonotypes from the early time point decreased in relative
frequency and rank at the late time point (Figs. 2b and 3a).
Instead, a different subset of CAR-T cell clonotypes, which were
initially of lower rank in the IP and at the early time point,
emerged as one of the most prevalent clonotypes at the late time
point (Fig. 3b). These findings highlight distinct differences in the
ability of infused CAR-T cells to either proliferate, survive, and/or
remain in blood after adoptive transfer.
Tracking the rank and relative frequency of CAR-T cell
clonotypes over time describes changes in the behavior of CAR-T
cell clones relative to each other but does not indicate whether the
absolute number of any given CAR-T cell clone is increasing or
decreasing in the blood. Therefore, we examined the absolute
count of individual CD8+ CAR-T cell clones in blood and
observed three patterns of clonal kinetics through the first 30 days
after infusion (Fig. 3c). We observed clones whose absolute
counts in blood progressively increased, clones that exhibited an
early and transient increase followed by a subsequent decrease,
and clones that progressively decreased after infusion. We did not
identify correlations between the clinical characteristics and
patterns of CAR-T cell clonal kinetics. The data indicates that
after infusion of a CAR-T cell product manufactured from bulk
CD4+ T cells and CD8+ TCM cells, there are CD8+ CAR-T cell
clones with different kinetics of accumulation in blood or loss
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from the blood after infusion. This could reflect cell intrinsic
differences in their capacity to proliferate, survive, or migrate to
tissues, or different levels of CAR expression on individual cells
that may dictate whether a cell is capable of recognizing tumor
targets and the effects of the tumor recognition on cell fate.
Integration site is not a dominant driver of clonal kinetics.
Vector integration site might be associated with clonal kinetics.
Therefore, we analyzed the lentiviral integration profile of CD8+
CAR-T cells isolated from the IPs and from blood after adoptive
transfer in ALL (n= 3) and non-Hodgkin lymphoma (NHL)
(n= 4) patients. A total of 55,382 unique integration events
(sites) were identified across all patients and samples. The
observed integration sites were consistent with lentiviral inte-
gration patterns previously described in human T-cell lines23.
Approximately 82.6% of all sites (45,771) were within genes and
integration in introns was more frequent than in exons (Fig. 4a).
Consistent with our findings from TCRB sequencing, different
clonotypes defined by integration site exhibited distinct in vivo
kinetic patterns after CAR-T cell infusion (Fig. 4b). We examined
whether these changes in clonotype abundance were associated
with distinct genomic loci of vector integration. We identified two
different groups of integration sites, sites that either increased or
decreased in relative abundance by at least 5-fold between the
IP and after infusion. Comparison of genes harboring these
integration sites revealed enrichment in many of the same bio-
logical pathways (Supplementary Fig. 2). However, genes in
biological pathways associated with lymphocyte activation, T cell
receptor (TCR) signaling, and regulation of type 1 interferon were
more enriched among genes harboring integration sites that
increased in relative abundance, and genes associated with T-cell
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Fig. 1 Clonal diversity of CD8+ CAR-T cells decreases after infusion. a CD8+/EGFRt+ CAR-T cell counts in the blood of patients who received CAR-T
cells manufactured from CD4+ and CD8+ TCM cells (n= 10 patients). Data represents the mean ± SEM. ALL acute lymphoblastic leukemia, NHL non-
Hodgkin lymphoma. b The Morisita index was calculated for pairwise comparisons of the CD8+ CAR-T cell repertoire between all samples. Left, Morisita
overlap index between the IP and the indicated times after adoptive transfer. Each line represents data from an individual patient. Right, heatmap of the
Morisita index. The Morisita index was lower at late compared to early times after infusion (paired Mann–Whitney test, p < 0.05). c Decreased clonal
diversity in CD8+ CAR-T cells after infusion. The Shannon entropy indices of the CD8+/EGFRt+ (CAR-T cell, left) and CD8+/EGFRt− (non-CAR-
expressing T cell, right) TCRB repertoires are shown. Statistical differences between samples were evaluated with paired t-tests. *p < 0.05, **p < 0.005,
***p < 0.001. d The relative frequencies of the top ten ranked clonotypes in the total CD8+ CAR-T cell TCRB repertoire in the IP and at the early and late
time points after infusion are presented in pie charts. The top ten clonotypes are ranked by the number of copies of the TCRB sequence in each sample; the
same color might not represent the same identical clonotype at each time point. Source data underlying Fig. 1a, c, and d are provided as a Source Data file.
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differentiation and the cellular response to UV were more enri-
ched among those harboring integration sites that decreased in
relative abundance (Supplementary Fig. 2). These data likely
reflect differences in genes that are active at the time of lentiviral
transduction.
A recent report identified dominance of a single infused CAR-
T cell clone in a single patient associated with integration into the
TET2 gene. Although integrations in the TET2 gene were
observed in our analyses (12 sites in 6 patients), none of these
integration sites were among the top 20 most abundant sites
identified in any patient or sample, indicating that integration
within the TET2 gene was not a key and frequent driver of clonal
expansion in our study. Furthermore, in two patients with highly
dominant TCRB clonotypes after infusion (ALL-2 and NHL-2),
we did not identify single integration sites that were responsible
for clonal dominance. No integration sites were found at a
frequency as high as that of the dominant TCRB clonotype. The
most dominant TCRB clonotypes in blood from ALL-2 and
NHL-2 at the early time point were 46.0% and 16.8%,
respectively. In contrast, in the same samples the highest
frequency integration sites in each patient only represented
2.75% and 5.2% of the total integration sites, respectively. These
data suggest that an integration site is unlikely to be the key driver
of clonal kinetics in our study.
Single-cell transcriptome analysis of CAR-T cells over time.
The different kinetic behaviors displayed by individual CD8+
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CAR-T cell clones after infusion may be associated with changes
in gene expression that occur over time during tumor elimina-
tion. To study the transcriptional profile of CD8+ CAR-T cells,
we selected four additional patients with durable persistence of
CAR-T cells following infusion of CD8+ CAR-T cells manu-
factured from either TCM cells or bulk CD8+ T cells for NHL
(n= 2) or chronic lymphocytic leukemia (CLL, n= 2), respec-
tively (Supplementary Table 1). Using the 10× Genomics plat-
form, we performed scRNA-seq on 62,167 CD8+ CAR-T cells
sorted based on truncated human epidermal growth factor
receptor (EGFRt) expression from the IP and blood at the early
(day 7–14), late (day 26–30), and very late (day 83–112) time
points after infusion. In all patients, a majority of the sequenced
cells expressed RNA encoding CD3D, CD3E, CD8A, and the
single-chain variable fragment (scFv) of the CD19 CAR construct
(Supplementary Fig. 3).
Visualization of single-cell transcriptomes by t-distributed
stochastic neighbor embedding (t-SNE) revealed that the
transcriptional profiles of CD8+ CAR-T cells in the blood at
the early, late, and very late time points progressively diverged
from that of CAR-T cells isolated from the IPs (Fig. 5a).
Differential gene expression (DEG) analysis revealed many
differences in gene expression between the IPs and CAR-T cells
isolated from blood after infusion (Fig. 5b). CD8+ CAR-T cells in
the IPs expressed higher levels of genes associated with the
glycolysis pathway, AP-1 transcription factors, and the early
activation marker CD69, likely due to in vitro stimulation by
CD19+ lymphoblastoid cell line (LCL) during manufacturing
(Fig. 5b). Compared with the IP, CAR-T cells at the early and late
time points after adoptive transfer expressed higher levels of
genes associated with cell-mediated cytotoxicity such as PRF1,
GZMB, and GZMK, which declined at the very late time point
(Fig. 5b). Gene set enrichment analysis (GSEA) further revealed a
transcriptional profile consistent with T-cell activation and an
effector response at the early time point that declined through the
late and very late time points (Fig. 5c). At later time points, there
was a decrease in enrichment of genes associated with the
tricarboxylic acid cycle and oxidative phosphorylation, which is
consistent with decreasing demand for ATP with declining T-cell
activation after tumor clearance. All four patients developed
profound B-cell aplasia after CAR-T cell infusion and showed
decreasing gene expression of MKi67 at late and very late time
points, consistent with a reduction in CAR-T cell proliferation
with depletion of target antigen (Fig. 5d).
We examined the transcriptome data to determine whether
there was evidence of exhaustion after infusion. We performed
GSEA using two different exhaustion gene sets (Supplementary
Table 3). One gene set compares exhausted CD8+ T cells from
chronic lymphocytic choriomeningitis virus infection to func-
tional CD8+ T cells after acute infection in mice24. The second
gene set compares exhausted, tonically signaling GD2.28z CAR-T
cells to functional GD2.BBz CAR-T cells generated from healthy
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human donors25. Comparison with the first gene set showed a
decrease in expression of the exhaustion gene signature over time
after infusion, whereas comparison with the second gene set did
not show any changes in expression of the exhaustion gene
signature over time (Fig. 5c). Overall, expression of an exhaustion
gene signature did not consistently increase over time after
infusion. Evaluation of the surface expression of seven inhibitory
receptors, including PD-1, LAG-3, TIM-3, KLRG1, TIGIT, 2B4,
and CD160, showed that CD8+ CAR-T cells co-expressed higher
numbers of inhibitory receptors after infusion, compared with the
IP (Fig. 5e). However, expression of multiple inhibitory receptors
by CD8+ CAR-T cells remained stable over time after infusion,
except in CLL-2, which showed a progressive increase in the
fraction of cells co-expressing four or more inhibitory receptors.
Contribution of infused CAR-T clusters to in vivo repertoire.
We investigated whether transcriptional signatures of CD8+
CAR-T cells in the IP might be associated with different clonal
kinetics after infusion. Principal component analysis (PCA) of
gene expression residuals demonstrated marked heterogeneity in
the transcriptional profiles of CD8+ CAR-T cells in the IP. After
infusion, transcriptional heterogeneity of CD8+ CAR-T cells
progressively declined in blood over time (Fig. 6a). Unsupervised
clustering of the scRNA-seq data further identified four tran-
scriptionally distinct clusters of CAR-T cells that were found in
the IP of all four patients (Fig. 6b) and were distinguished by
differential expression of T-cell activation-, cytotoxicity-, mito-
chondrial-, and cell cycle-associated genes (Fig. 6c). Cells in
cluster 2 displayed higher expression of genes associated with
cytotoxicity, whereas cells in cluster 4 were distinguished by
higher expression of genes associated with proliferation, com-
pared with cells in clusters 1 and 3. When we assigned a cell cycle
score to each cell, CAR-T cells in cluster 4 entirely comprised
single cells in the S or G2M phase (Supplementary Fig. 4a)
confirming that cluster 4 is composed of cycling/proliferating
CD8+ CAR-T cells. Pseudotime and RNA velocity analyses of
CAR-T cells in the IP did not yield clearly defined trajectories to
indicate a developmental relationship between clusters, even after
correcting the dataset for cell cycle- and mitochondrial-associated
genes with pseudotime analysis (Supplementary Fig. 4b, c).
To link distinct transcriptional programs with clonal expansion
and persistence after adoptive transfer, we used paired TCR
sequences from the scRNA-seq data to track the clonal behavior
of CD8+ CAR-T cells after infusion in NHL-6 and NHL-7. We
first identified CD8+ CAR-T cell clonotypes in the IP that had a
significantly higher or lower frequency at the early time point,
designated as IRF (increased relative frequency) or DRF
(decreased relative frequency) clonotypes, respectively (Fig. 7a
and Supplementary Table 4)26. DEG analysis showed that IRF
clones displayed higher expression of CCL4, CD27, IFNG, and
cytotoxicity-associated genes (Fig. 7b). Given that IRF clones
expressed higher levels of cytotoxicity-associated genes, we
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determined the distribution of IRF and DRF clones among the
four transcriptionally distinct clusters in the IP. Both IRF and
DRF clones were present in all four clusters (Fig. 7c). However, a
majority of the IRF clones in both patients were detected in
clusters 2 and 4 (NHL-6: 85.6%, NHL-7: 84.6%), which expressed
high levels of genes associated with cytotoxicity and proliferation,
respectively (Fig. 7c), despite the finding that these clusters only
comprised 42.7% and 27.1% of cells in the IP in NHL-6 and
NHL-7 (Fig. 6b), respectively. In contrast, clusters 1 and 3
harbored few IRF clones.
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GSEA using indicated gene sets was performed on CD8+ CAR-T cells isolated from the IP and blood at distinct time points after adoptive transfer. A
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isolated at the early, late, and very late time points after infusion. Source data underlying Fig. 5e is provided as a Source Data file.
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Although IRF clonotypes were identified by their increasing
representation at the early time point after infusion, it remained
unknown whether IRF clones could persist and contribute to the
CD8+ CAR-T cell pool at the late and very late time points. In
NHL-6, 100% (29 of 29) of the IRF clonotypes were detected at
both the late and very late time points, whereas only 22% (15 of
67) and 9% (6 of 67) of the DRF clonotypes were present at the
late and very late time points, respectively (Table 1). In NHL-7,
100% of the IRF clonotypes were detected at the late time point
and 53% (10 of 19) were present at the very late time point. In
contrast, only 5% (3 of 59) and 3% (2 of 59) of the DRF
clonotypes were present at the late and very late time points,
respectively (Table 1).
To further determine the contribution of transcriptionally
distinct subsets in the IP to the CD8+ CAR-T cell pool after
infusion, we identified clonotypes in the IP that were subsequently
present or not present at the early, late, or very late time points
after infusion. As time after infusion increased, there was a
progressive increase in the fraction of persisting clonotypes that
originated from cluster 2 in the IP (Fig. 7d). Thus, transcriptionally
distinct subsets of infused CAR-T cells differ in their contributions
to the CAR-T cell pool in blood after adoptive transfer.
Discussion
Expansion of CD19-specific CAR-T cells in vivo in response to
antigen encounter is a key factor associated with clinical response
and toxicities of CAR-T cell therapy4,6,11,27. Previous studies have
reported associations between functional attributes in pooled
CAR-T cell populations and clinical response8,28,29, but no studies
have examined factors that impact expansion of distinct clones
within individual patients. In this study, we examined the in vivo
behavior of distinct CAR-T cell clones within individual patients.
This approach allowed direct assessment of transcriptional attri-
butes in infused cells associated with clonal expansion in individual
patients, regardless of the anti-tumor response, which might be
influenced by the tumor burden and tumor microenvironment.
Using TCRB sequencing, we examined the behavior of indi-
vidual CD8+ CAR-T cells after adoptive transfer in patients that
received CD8+ CAR-T cells manufactured from CD8+ TCM cells,
to provide greater uniformity in the starting population. As
expected, we found that CAR-T cells in the IPs were polyclonal
and this polyclonality was maintained in the persisting CAR-T
cells in the patients. However, individual clones exhibited dif-
ferent patterns of expansion and contraction in vivo, suggesting
that even when starting with a uniform subset of T cells, distinct
clones have better capacity to proliferate, survive, and/or remain
in the blood after infusion. It remains unclear whether clones that
are dominant in the blood are also highly represented at the site
of tumor. Additional studies on the CAR-T cell repertoire in the
bone marrow and lymph nodes will be important to address the
contribution of clones in the IPs to the CAR-T cell pool at the site
of the tumor.
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scRNA-seq of CD8+ CAR-T cells revealed that the transcrip-
tional profile of CAR-T cells in the blood progressively diverged
from that of the IP. Early after infusion, transferred CD8+ CAR-T
cells displayed a gene expression profile consistent with activated
CD8+ effector T cells, which reflects robust T-cell activation upon
antigen encounter. As the tumor and normal CD19+ B cells were
eliminated, transcriptional signatures of CAR-T cell activation
and proliferation progressively declined without enrichment of an
exhaustion gene signature or an increase in co-expression of
inhibitory receptors at later times after infusion. Further studies
in a larger cohort of patients are required to determine the
exhaustion state of CAR-T cells after infusion and whether the
single-cell transcriptional profile of CAR-T cells in the blood are
representative of CAR-T cells in the tumor.
Single-cell analysis of CD8+ CAR-T cells in the IPs from four
patients in whom CAR-T cells were manufactured from CD8+
TCM (n= 2) or bulk CD8+ T cells (n= 2) revealed the presence
of four transcriptionally distinct CAR-T cell clusters. These
clusters were observed in all patients, regardless of the phenotype
of the starting CD8+ T-cell population used in CAR-T cell
manufacturing. The presence of contaminating cells appears
unlikely to have influenced the observed transcriptional hetero-
geneity as the analyzed single cells were sorted to high purity and
expressed RNA encoding CD3 subunits, CD8, and the FMC63-
derived scFv in the CAR. These clusters were distinguished
primarily by the expression of activation-, cytotoxicity-, mito-
chondrial-, and cell cycle-associated genes. Higher expression of
mitochondrial genes in cluster 3 is indicative of pre-apoptotic
cells, whereas higher expression of cell cycle-associated genes in
cluster 4 signifies cells in the S/G2M phase of the cell cycle. These
transcriptionally different cell states may in part be due to sto-
chastic effects of T-cell stimulation and activation during man-
ufacturing, or different levels of CAR expression in individual
cells30. Studies to evaluate stimulation, transduction, and culture
conditions that result in cells with distinct transcriptional attri-
butes may be valuable in optimizing manufacturing strategies.
A number of factors including cell intrinsic properties might
contribute to differences in the capacity of CAR-T cells to expand
and persist after adoptive transfer. The site of lentiviral vector
integration has been reported to affect clonal expansion in which
vector integration within the TET2 gene was found to be the key
driver of unique clonal expansion in a single patient19. Although
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Table 1 The proportion of IRF and DRF clones that were
present at the late and very late time points after infusion.
IRF clonotypes DRF clonotypes
NHL-6
Late time point
29/29
(100%)
15/67
(22%)
NHL-6
Very late time point
29/29
(100%)
6/67
(9%)
NHL-7
Late time point
19/19
(100%)
3/59
(5%)
NHL-7
Very late time point
10/19
(53%)
2/59
(3%)
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our data cannot exclude the possibility of integration events
contributing to clonal kinetics, they do not point to a single vector
integration site as the major driver of clonal proliferation in this
patient cohort. However, the finding that expanding clonotypes
were enriched in integration sites located in genes associated with
lymphocyte activation is consistent with robust anti-CD3/CD28-
mediated T-cell activation prior to lentiviral transduction being
more often associated with subsequent clonal proliferation.
Using paired gene expression and TCR sequences obtained
from scRNA-seq data, we tracked the fate of individual CD8+
CAR-T cell clonotypes between the IP and the blood over time
after infusion. The majority of IRF clones whose relative abun-
dance increased early after infusion originated from clusters 2 and
4 in the IP, which expressed higher levels of genes associated with
cytotoxicity and proliferation. Interestingly, a cytotoxicity gene
signature was also highly expressed at the early and late time
points relative to the IP, which might be driven by expansion of
IRF clones continuing to express this gene signature. IRF clones
also displayed higher gene expression of CD27, which supports
recent findings that the frequency of CD27+ CD8+ T cells in the
starting T-cell population and the IP correlates with better clinical
outcomes in CLL patients29. Importantly, we found that in con-
trast to DRF clonotypes, a large proportion of IRF clonotypes
were also present at the very late time point, suggesting that IRF
clones can persist in the blood beyond 3 months after infusion.
Additional studies are needed to determine whether IRF clones
might also contribute to the CAR-T cell pool at the tumor site
and to better understand differences between the transcriptional
profiles of CAR-T cells in the tumor compared with blood. Our
data reveals that within infused CAR-T cells of defined CD4+:
CD8+ composition, CD8+ CAR-T cells in the IP that acquired
effector function and proliferated during manufacturing expand
and survive in vivo, contributing greatly to the CAR-T cell pool
and the anti-tumor response early and late after adoptive transfer.
Our findings demonstrate the potential for scRNA-seq to provide
unique insights into the in vivo behavior of CAR-T cells after
adoptive transfer, which may guide future studies to improve
CAR-T cell immunotherapy.
Methods
Patient characteristics and treatment regimen. We studied a subset of adult
patients with relapsed and refractory B-cell ALL, NHL, or CLL, who received
CD19-specific CAR-T cells in a phase 1 clinical trial (NCT01865617, Supple-
mentary Table 1)4,6,11 and had sufficient numbers of CD8+ CAR-T cells in the
blood after infusion at the early (day 7–14) and late (day 26–30) time points for
TCRB repertoire analysis, as well as at the very late (day 83–112) time point for
single-cell transcriptome analysis. The study was conducted in accordance with the
principles of the Declaration of Helsinki and with the approval of the Fred
Hutchinson Cancer Research Center Institutional Review Board. CD19-specific
CAR-T cells were manufactured from isolated bulk CD4+ T cells and either TCM or
bulk CD8+ T cells, as previously described4,6,11. In brief, T-cell subsets were iso-
lated from leukapheresis products, stimulated with paramagnetic beads (CTS
Dynabeads CD3/CD28), and then transduced with a lentivirus incorporating a
transgene encoding a CD19-targeting CAR containing a 4-1BB/CD3ζ signaling
domain and an EGFRt, which enabled identification of transduced cells by flow
cytometry (Supplementary Fig. 5a)31. CAR-T cells were stimulated during culture
with an irradiated, allogeneic CD19+ LCL cell line and were formulated 9–11 days
after LCL stimulation in a 1:1 ratio of CD4+:CD8+ CAR-T cells for infusion4,6,11.
CAR-T cell isolation, enumeration, and immunophenotyping. CD8+ CAR-T
cells for TCRB sequencing or scRNA-seq were isolated from cryopreserved aliquots
of the IP or peripheral blood mononuclear cell (PBMC), washed in RPMI con-
taining 50 U/ml of benzonase (Novagen), incubated with Live/Dead Fixable Violet
stain, then stained with biotinylated anti-EGFRt monoclonal antibody (cetuximab),
followed by fluorochrome-conjugated streptavidin and antibodies to CD4 and
CD8. CD8+ CAR-T cells were isolated as CD8+/CD4−/EGFRt+ events in a singlet
lymphocyte forward-scatter (FS)/side-scatter (SS) gate using a BD Aria 2 flow
sorter (Supplementary Fig. 5b).
The absolute CD8+ CAR-T cell count in blood was determined by multiplying
the percentage of CD8+ CAR-T cells in a viable CD45+ lymphocyte FS/SS gate by
the absolute lymphocyte count determined from a complete blood count
performed on the same day. The absolute count of CD8+ CAR-T cells distributed
in blood immediately after infusion was determined by dividing the number of
infused CD8+ CAR-T cells by the estimated total blood volume of the recipient
(BloodVol=Weight × AvgBloodVol; AvgBloodVol for women= 65 ml/kg and
men= 75 ml/kg).
For analysis of the surface immunophenotype of CAR-T cells, aliquots of the
IPs and PBMCs were stained with Live/Dead Fixable Blue stain followed by
fluorochrome-conjugated antibodies to EGFRt, CD45, CD3, CD4, CD8, LAG-3,
PD-1, TIM-3, KLRG1, TIGIT, 2B4, and CD160 with analysis using a BD
FACSymphony flow cytometer.
TCRB sequencing. Sequencing of the TCRB CDR3 region in CD8+ CAR-T cells
was performed by Adaptive Biotechnologies, with subsequent analysis using R. To
compare TCRB diversity between samples of different sizes, we downsampled
CDR3 sequences to the minimum number of productive sequences, downsampling
1000 times for each sample22. For each downsampled dataset, we calculated the
Shannon entropy index and the median Shannon entropy was used for compar-
isons between samples. The relative frequency of a CD8+ CAR-T cell clonotype in
a sample was defined as the fraction of the total CD8+ CAR-T cell TCRB sequences
that was occupied by the clonotype. The absolute count of an individual CAR-T
cell clone in blood was determined by multiplying the relative frequency of the
clonotype by the absolute CAR-T cell count.
Integration site analysis. Integration site analysis (ISA) was performed on CD8+
T cells isolated from the IP and from blood after adoptive transfer. Processing of
gDNA to amplify integration loci included MGS-PCR methods32. Briefly, ampli-
fication of integration loci occurs through two PCR reactions. In the first PCR, the
forward primer is aligned to the lentivirus long terminal repeat (LTR) and the
reverse primer is aligned to a synthetic linker oligonucleotide that was assembled
and ligated to fragmented genomic DNA. The forward primer (LTR) in the second
PCR is nested and aligns to the 3′-end of the sequence amplified by the LTR primer
used in the first PCR. The reverse primer for the linker cassette is the same for both
reactions. Primer sequences are listed in Supplementary Table 5.
ISA reads were sequenced using the Illumina Miseq next-generation sequencing
platform for paired-end reads. A detailed list of samples is included in the dataset
available for download (link to be provided at time of publication). For Illumina
data, the forward and reverse reads were stitched using PEAR with the -q 30 option
to trim sequence reads after two bases with a quality score below 30 were
observed33. Stitched FASTQ files and raw FASTA files for all sequencing data were
filtered using a custom c++ program. Each read was compared with the reference
provirus LTR sequence. Reads with <90% match to LTR sequence were discarded.
The LTR sequence was trimmed off of remaining reads. Reads were then compared
with vector sequence (as opposed to genomic insertion sequences). Reads with
≥80% match to vector sequence were discarded. Remaining reads were output in
FASTA format for alignment.
Identified genomic fragments were aligned to the human Genome Reference
Consortium Human Build 38 (GRCh38) [RefSeq Assembly: GCF_000001405.26],
to determine the chromosome, locus, and orientation of integration (e.g.,
Chr14_8020175_+ ). GRCh38 was downloaded from the UCSC genome browser
(http://genome.ucsc.edu/)34: filtered and trimmed sequence reads were aligned to
the reference genome using BLAT with options -out= blast8, -tileSize= 11,
-stepSize= 5, and -ooc= hg11-2253.ooc.35
The hg11-2253.ooc file contains a list of 11-mers occurring at least 2253 times
in the genome to be masked by BLAT and was generated using the following
command:
$blat hg38.2 bit /dev/null /dev/null -tileSize= 11 -stepSize= 5 -makeOoc=
hg11-2253.ooc -repMatch= 2253
as recommended by UCSC [http://genome.ucsc.edu/goldenpath/help/blatSpec.
html35 and http://genome.ucsc.edu/FAQ/FAQblat.html#blat6]. Resulting blast8
files were parsed using a custom python script. Any read with BLAT alignment
length <30 or alignment start >10 is discarded. The top scoring alignment and all
alignments within 95% of the top score were saved for each read. The ratio of the
best alignment to the second-best alignment is the degree with which the insert can
be mapped to one location in the genome (multi-align-ratio). Starting with the
highest count reads, reads with matching alignments were combined. Reads with
multiple possible alignments were not discarded at this point but were grouped
together with other reads with the same alignment(s). For each group of reads with
matching alignments, the original FASTA sequence files were read, then the
sequences were aligned with Clustal Omega36,37. This alignment was used to build
a single consensus sequence for the alignment group. The consensus sequence was
then used to search the pool of all sequences that could not be aligned by BLAT
and any sequence with ≥90% identity was merged into the group. Starting with the
highest count groups and comparing with the lowest count groups, groups with
≥90% sequence similarity were merged. Finally, when comparing all sequence files
for one test subject, all groups with exact alignment matches were merged into one
clone ID. Clone IDs with exact consensus sequence matches were also merged.
Non-uniquely aligned groups (multi-align-ratio ≥ 0.9) that had ≥90% similar
reference sequences were also merged into a single Clone ID38.
ISA clone contributions were calculated by dividing the number of sequence
reads for each clone by the total number of sequence reads associated with any
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clone ID for the sample. The mean maximum frequency of clones was calculated. A
data frame was constructed including three columns: (1) days after treatment (or
IPs); (2) clone frequency in the sample; and (3) clone identifier (genomic locus).
The data frame was visualized using the R package ggplot2 (http://ggplot2.org/).
We then used normalization to convert the number of sequence reads
associated with each clone to frequencies for each sample. At this point, we
determined the maximum contribution frequency of each clone observed. The
contribution frequencies for each of these clones at each sampling time point is
recorded. Each clone has two entries in the data frame, one for each sampling time
point, with 0% values entered where sequence reads were not observed. This is
repeated for every clone identified in any sample from the same subject.
Visualization is then done using ggplot2 (http://ggplot2.org/) using
geom_area/geom_ribbon. Clones contributing ≥1% of the detected pool in any
sample from the same subject are denoted by a color ribbon. All remaining
identified clones are grouped into the gray ribbon at the top of each plot.
Integration sites that increased in relative abundance by at least fivefold between
the IPs and after infusion were identified and combined across all patients. Gene
Ontology (GO) enrichment analysis was performed on this list of expanding
integration sites using the Gene Ontology Consortium website (http://
geneontology.org/) to find significantly enriched pathways39–41. This analysis was
repeated for integration sites that decreased in relative abundance by at least
fivefold between the IP and after infusion. Statistics were performed by the GO
consortium website using false discovery rate (FDR) and corrected p-values
associate with each pathway was represented in a heatmap.
Transcriptional profiling of single CD8+ CAR-T cells. Construction of scRNA-
seq libraries was performed using the Chromium Single Cell 5′-library and V(D)J
enrichment kit as per manufacturer’s instructions (10× Genomics). For each
sample, a 5′-gene expression library and an enriched V(D)J library was constructed
and sequenced using the HiSeq 2500 platform (Illumina). The Cell Ranger Single-
Cell Software Suite (version 2.1.0) was used to perform sample demultiplexing,
barcode processing, and single-cell gene counting. Raw base BCL files were
demultiplexed using the Cell Ranger mkfastq pipeline into sample-specific FASTQ
files. FASTQ files were processed individually using the Cell Ranger count pipeline,
which used the STAR software42 to align reads to the pre-built GRCh38 human
reference genome provided by Cell Ranger (10× Genomics). Aligned reads were
then filtered for valid cell barcodes and unique molecular identifiers (UMIs). Cell
barcodes 1 Hamming distance away from a list of known barcodes were con-
sidered. UMIs with a sequencing quality score >10% without homopolymers were
retained as valid UMIs. A UMI with 1 Hamming distance from another UMI with
more reads, for the same gene and same cell, was corrected to the UMI with more
reads. All samples were aggregated using the Cell Ranger aggr pipeline resulting in
one gene-barcode count matrix to be used for downstream analyses. A correction
for sequencing depth was performed during the aggregation43.
Following sequence alignment and filtering, data from cells with unique gene
counts <200, a percentage of mitochondrial genes >20% or >40,000 UMIs were
removed. Based on these criteria, 2340 cells were discarded, resulting in 62,167
CD8+ single CAR-T cells for analysis. Standard analyses were performed using the
Seurat R package44. Only genes with at least one UMI count detected in at least
three cells were used. A library-size normalization was performed for each cell.
UMI counts were scaled by the total expression in each cell and multiplied by
10,000. The data were then log-transformed and corrected for unwanted sources of
variation such as the number of detected UMIs, percentage of mitochondrial gene
content, and different patient origin using the ScaleData R function as described in
the Seurat manual44. The corrected-normalized gene-barcode matrix was used to
perform PCA, clustering, and t-SNE analyses, whereas the normalized gene-cell
barcode matrix was used for the MAST analysis as described below.
The top 1000 most variable genes were kept as inputs to compute the PCA. The
top 15 principal components were then down-selected for t-SNE visualization and
clustering. One thousand iterations of the t-SNE Barnes-hut implementation using
a perplexity value of 30 were performed. Cell clustering was performed using a
graph-based clustering method implemented in Seurat (FindClusters R function—
share nearest neighbor modularity optimization-based clustering algorithm) using
default parameters.
DEG analysis and GSEA analysis were performed using the MAST R package45.
Within each patient, a logistic regression model was used to test the DEG rate
between groups, while a Gaussian generalized linear model described expression
conditionally on non-zero expression estimates. The model was also corrected for
the cellular detection rate, defined as the proportion of expressed genes in a given
cell. Genes were declared significantly differentially expressed at a FDR of 5% and
absolute log2 fold change > log2(1.5). Gene sets were declared significant at an FDR
of 1%, absolute continuous Z-score > log2(2.5) and absolute discrete Z-score > log2
(2.5). Blood transcriptome modules46 and Kyoto Encyclopedia of Genes and
Genomes (KEGG)- and T-cell-related pathways24,25,47 (Supplementary Table 4)
were used as gene sets. KEGG gene sets were downloaded from MSigDB
database48.
The CellCycleScoring R function from the Seurat R package was used to assign
a cell cycle score to each cell. This function calculates S and G2M scores and
predicts classification of each cell in either S, G2M, or the G1 phase.
Single-cell trajectory analysis. The latest version of the Monocle 3R package was
used to construct single-cell trajectories of cells from clusters in the IPs49–51. The
first step in the Monocle 3 workflow (https://cole-trapnell-lab.github.io/monocle3/
docs/trajectories/) was to normalize and pre-process the data. Using the align_cds
R function, patient ID was selected as the alignment group and the data were
corrected for cell cycle scores, the number of detected UMIs, and the percentage of
mitochondrial genes. Next, the dimensionality of the data is reduced using uniform
manifold approximation and projection with the reduce_dimension R function.
Trajectory inference analysis was performed using the cluster_cells and learn_graph
R functions using the default settings.
For each patient, the dropEst pipeline was used to generate count matrices that
calculate the fraction of intronic and exonic UMIs separately52. The 10× bam files
were used as inputs with the following options -V -C 10000 -m -f. Separate .rds files
containing intronic, exonic, or exon/intron spanning matrices were produced and
used as inputs for RNA velocity analysis. The velocyto R package was then used to
analyze the expression dynamics of cells in the IPs53. Cells from clusters 1, 2, 3, and
4 representing the IPs were used as inputs. After filtering genes using the filter.
genes.by.cluster.expression R function for both intronic and exonic matrices,
estimation of RNA velocity was performed using the gene.relative.velocity.estimates
R function with kCells of 25, fit.quantile of 0.02, and PCA projections from the
previous Seurat analysis as proposed in the online tutorial for the cell.dist
parameter. RNA velocities were then visualized on our existing embedding (t-SNE)
using the show.velocity.on.embedding.cor R function.
TCRB sequencing of single CD8+ CAR-T cells. Generation of TCRB sequences
and annotations in single CAR-T cells was performed on scRNA-seq data by Cell
Ranger vdj. Cell Ranger vdj takes as inputs FASTQ files previously produced from
Cell Ranger mkfastq and performs V(D)J sequence assembly and paired clonotype
calling. TCRB sequence analysis was performed using R. The input data consisted
of the observed number and fraction of each TCRB sequence in each sample. We
defined IRF and DRF clonotypes as those with higher or lower relative TCRB
clonotype abundance, respectively, in CAR-T cells at the early time point compared
with the IPs (Fisher’s exact test, FDR of 5%).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
TCR-seq data are provided as a Source Data file. All sequence data obtained in the
integration site analysis study are available at National Center for Biotechnology
Information Sequence Read Archive (NCBI SRA) under accession number
PRJNA589633. scRNA-seq data are available at National Center for Biotechnology
Information Gene Expression Omnibus (NCBI GEO) under accession number
GSE125881. The source data underlying Figs. 1a, c, d, 2a, b, 3a-c, 5e, and 7c, and
Supplementary Figs. 1 and 2 are provided as a Source Data file.
Code availability
All custom R and Python codes are available on request or at https://github.com/
ValentinVoillet/CAR-T. All other codes are publicly available and cited in the
appropriate methods description.
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